BTIG Maintains Buy on Gracell Biotechnologies, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Gracell Biotechnologies (NASDAQ:GRCL) and raises the price target from $18 to $20.
June 13, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG maintains a Buy rating on Gracell Biotechnologies and raises the price target from $18 to $20.
The raised price target by BTIG analyst Justin Zelin indicates a positive outlook for Gracell Biotechnologies. This news is likely to have a positive impact on the stock price in the short term as it shows increased confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100